Parametric Portfolio Associates’s Century Therapeutics IPSC Stock Holding History

Parametric Portfolio Associates’s Portfolio IPSC Stock Details IPSC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$146K	Buy	+11,589	New	+$154K	﹤0.01%	3501

Other funds holding IPSC

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Parametric Portfolio Associates's IPSC Position: Q1 2022 in Review

Parametric Portfolio Associates opened a new position in Century Therapeutics (IPSC) in Q1 2022: 11,589 shares worth $146K. The stake represents ﹤0.01% of the portfolio and ranks #3501 among its holdings.

52 funds tracked by Wall St. Rank hold IPSC as of Q1 2022.

Parametric Portfolio Associates held 11,589 shares of Century Therapeutics worth $146K as of Q1 2022.
Century Therapeutics was a new Parametric Portfolio Associates position in Q1 2022.
Century Therapeutics made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #3501 holding.
52 funds tracked by Wall St. Rank held Century Therapeutics as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.